Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial

Mann K, Ackermann K, Diehl A, Ebert D, Mundle G, Nakovics H, Reker T, Richter G, Schmidt LG, Driessen M, Rettig K, et al. (2006)
Psychopharmacology 184(1): 115-121.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Mann, K.; Ackermann, K.; Diehl, A.; Ebert, D.; Mundle, G.; Nakovics, H.; Reker, T.; Richter, G.; Schmidt, L. G.; Driessen, MartinUniBi ; Rettig, K.; Opitz, K.
Alle
Abstract / Bemerkung
Objectives The involvement of the central cholinergic system in alcohol abuse behavior is well known. It is possible that the reinforcing effects of ethanol are partially mediated by nicotinic receptors, which modulate neurotransmitter release. It was demonstrated that the application of a cholinesterase inhibitor reduces alcohol consumption in alcohol-preferring rats. This suggests that galantamine (GAL), a cholinesterase inhibitor, could be effective when seeking to prolong abstinence in recently detoxified alcoholics. This study represents the first reported clinical trial of a cholinergic drug in alcohol-relapse prevention. Patients and methods We investigated the efficacy and safety of GAL by conducting a 24-week randomized, placebo-controlled, multicentric clinical trial on 149 recently detoxified alcoholics. Survival analyses (Kaplan–Meier) were performed to reveal evidence of prolonged abstinence periods in patients who received GAL. Results Our findings did not support our hypothesis. GAL did not extend the time to first severe relapse. However, additional post hoc analyses suggest that relapsed patients treated with GAL consume less ethanol per drinking day than patients treated with placebo. Conclusions GAL seems to be ineffective when used in relapse prevention of detoxified alcoholics. It is possible that alcohol needs to be “on board” for GAL to be beneficial. This could explain why our post hoc analysis showed that GAL possibly reduces the alcohol consumption of relapsers. If confirmed, GAL could play a role in the reduction of harmful alcohol use and at-risk consumption.
Erscheinungsjahr
2006
Zeitschriftentitel
Psychopharmacology
Band
184
Ausgabe
1
Seite(n)
115-121
ISSN
0033-3158
eISSN
1432-2072
Page URI
https://pub.uni-bielefeld.de/record/2963406

Zitieren

Mann K, Ackermann K, Diehl A, et al. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology. 2006;184(1):115-121.
Mann, K., Ackermann, K., Diehl, A., Ebert, D., Mundle, G., Nakovics, H., Reker, T., et al. (2006). Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology, 184(1), 115-121. https://doi.org/10.1007/s00213-005-0243-9
Mann, K., Ackermann, K., Diehl, A., Ebert, D., Mundle, G., Nakovics, H., Reker, T., Richter, G., Schmidt, L. G., Driessen, M., et al. (2006). Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology 184, 115-121.
Mann, K., et al., 2006. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology, 184(1), p 115-121.
K. Mann, et al., “Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial”, Psychopharmacology, vol. 184, 2006, pp. 115-121.
Mann, K., Ackermann, K., Diehl, A., Ebert, D., Mundle, G., Nakovics, H., Reker, T., Richter, G., Schmidt, L.G., Driessen, M., Rettig, K., Opitz, K., Croissant, B.: Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology. 184, 115-121 (2006).
Mann, K., Ackermann, K., Diehl, A., Ebert, D., Mundle, G., Nakovics, H., Reker, T., Richter, G., Schmidt, L. G., Driessen, Martin, Rettig, K., Opitz, K., and Croissant, B. “Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial”. Psychopharmacology 184.1 (2006): 115-121.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 16328375
PubMed | Europe PMC

Suchen in

Google Scholar